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Early discontinuation of endocrine therapy for
breast cancer: who is at risk in clinical practice?
Anna Kemp1*, David B Preen1, Christobel Saunders2, Frances Boyle3, Max Bulsara4, Eva Malacova1
and Elizabeth E Roughead5

Abstract
Purpose: Despite evidence supporting at least five years of endocrine therapy for early breast cancer, many
women discontinue therapy early. We investigated the impact of initial therapy type and specific comorbidities
on discontinuation of endocrine therapy in clinical practice.
Methods: We identified women in a population-based cohort with a diagnosis of early breast cancer and an
incident dispensing of anastrozole, letrozole or tamoxifen from 2003–2008 (N = 1531). Pharmacy and health
service data were used to determine therapy duration, treatment for pre-existing and post-initiation comorbidities
(anxiety, depression, hot flashes, musculoskeletal pain, osteoporosis, vaginal atrophy), demographic and other
clinical characteristics. Time to discontinuation of initial, and any, endocrine therapy was calculated. Cox regression
determined the association of different characteristics on early discontinuation.
Results: Initial endocrine therapy continued for a median of 2.2 years and any endocrine therapy for 4.8 years.
Cumulative probability of discontinuing any therapy was 17% after one year and 58% by five years. Initial tamoxifen,
pre-existing musculoskeletal pain and newly-treated anxiety predicted shorter initial therapy but not discontinuation
of any therapy. Early discontinuation of any therapy was associated with newly-treated hot flashes (HR = 2.1,
95% CI = 1.3–3.3), not undergoing chemotherapy (HR = 1.4, 95% CI = 1.1–1.8) and not undergoing mastectomy
(HR = 1.5, 95% CI = 1.2–1.8).
Conclusions: Less than half of women completed five years of endocrine therapy. Women at greatest risk of
stopping any therapy early were those with newly-treated hot flashes, no initial chemotherapy, or no initial
mastectomy. This suboptimal use means that the reductions in recurrence demonstrated in clinical trials may not
be realised in practice.
Keywords: Persistence; Adherence; Tamoxifen; Aromatase inhibitors; 45 and up study

Background
Endocrine therapy is the foundation of post-surgical
treatment for women with hormone-dependent early
breast cancer (Cheung 2007). Clinical trials clearly demonstrate that endocrine therapy halves the risk of recurrence and reduces cancer-related mortality when used for
at least five years (ATAC Trialists’ Group 2005; Bliss et al.
2012; Coates et al. 2007; Davies and Adjuvant Tamoxifen:
Longer Against Shorter (ATLAS) Collaborative Group
2013; Forbes et al. 2008; Gray and aTTom Collaborative
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Group 2013). Women using endocrine therapy for shorter
time periods are at increased risk of recurrence and have
higher mortality (Hsieh et al. 2014; McCowan et al. 2008;
Swedish Breast Cancer Cooperative Group 1996; Yood
et al. 2008). Despite strong empirical support for at least
five years of endocrine therapy, early discontinuation of
therapy in clinical practice has been reported in many
European and North American studies (Hershman et al.
2010; Huiart et al. 2011; McCowan et al. 2008; Owusu
et al. 2008; Partridge et al. 2008; van Herk-Sukel et al.
2010). A review of endocrine therapy duration of use
outside of clinical trials reported that between 13%
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and 20% of women had discontinued therapy within
one year, and 31%–73% had discontinued within five years
(Murphy et al. 2012).
A number of demographic and clinical factors have been
associated with early discontinuation including younger
and older age (<45 years or >70 years) (Barron et al. 2007;
Hershman et al. 2010; Nekhlyudov et al. 2011; van HerkSukel et al. 2010), being married (Kimmick et al. 2009),
social disadvantage (Nekhlyudov et al. 2011), having a
node-negative tumour (Kimmick et al. 2009), not undergoing chemotherapy or mastectomy (Barron et al. 2007;
Hershman et al. 2010), and number of comorbidities
(Demissie et al. 2001; Hershman et al. 2010; Kimmick
et al. 2009; Neugut et al. 2011; van Herk-Sukel et al. 2010).
Number of comorbidities has typically been ascertained
using the Charlson comorbidity index (Charlson et al.
1987) or number of prescriptions used prior to commencing therapy, and reported associations with persistence to
endocrine therapy have been mixed. Endocrine therapy
may cause or exacerbate specific conditions including anxiety (Grunfeld et al. 2005; Güth et al. 2011), depression
(Grunfeld et al. 2005), hot flashes (Grunfeld et al. 2005;
Güth et al. 2011), musculoskeletal pain (Chim et al. 2013;
Güth et al. 2011;), osteoporosis (Bell et al. 2013), and vaginal atrophy (Fallowfield et al. 2004). Self-report suggests
that these comorbidities are the reason some women
discontinue therapy (Murphy et al. 2012) but the role
of specific comorbidities has not been examined in
observational studies of discontinuation.
A number of observational studies of endocrine therapy duration have ended follow-up when a woman’s
initial therapy is discontinued, reflecting the prominence
of tamoxifen therapy until the mid-2000’s (Barron et al.
2007; McCowan et al. 2008; Partridge et al. 2003; van
Herk-Sukel et al. 2010). There are few data to indicate
whether characteristics associated with discontinuation
of initial therapy (including initial therapy type) are associated with discontinuation of any endocrine therapy
outside of clinical trials. One study of 4917 women with
early breast cancer compared characteristics predicting
discontinuation of initial therapy and any therapy (van
Herk-Sukel et al. 2010). The authors reported that
having ≥2 comorbidities was associated with shorter
duration of any endocrine therapy but found no association
with discontinuation of initial therapy (van Herk-Sukel
et al. 2010). Another study compared duration of initial
therapy in women commencing with tamoxifen or an aromatase inhibitor (AI: anastrozole, letrozole or exemestane)
and reported greater discontinuation for tamoxifen users
than those taking AIs at five years (31% vs. 19%) (Huiart
et al. 2011).
The aim of this study was to determine duration of
use for initial endocrine therapy, and any endocrine
therapy by women treated for early breast cancer in
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clinical practice; and the impact of initial therapy type
and specific comorbidities on early discontinuation.

Methods
Study population

Participants were drawn from the 45 and Up Study cohort, a population-based cohort of approximately 267,000
adults (143,014 women) aged ≥45 years residing in New
South Wales (NSW), Australia (45 and Up Study Collaborators 2008). All cohort members provided written
consent to join the 45 and Up Study, have their routinelycollected health data linked, and for these data to be
provided to third-party researchers for approved projects.
Data sources and linkage

We accessed unit-record, linked data from: i) the 45 and
Up Study baseline survey, ii) NSW Central Cancer
Registry, iii) NSW Admitted Patient Data Collection (all
admissions to public and private hospitals), iv) Pharmaceutical Benefits Scheme (PBS) claims (all subsidised
medicines), v) Medicare Benefits Schedule (MBS) claims
(all subsidised outpatient consultations and investigations), and vi) NSW Registry of Births, Deaths, and
Marriages. PBS and MBS data were supplied by the
Department of Human Services, and remaining datasets
were linked by the NSW Centre for Health Record Linkage
(Centre for Health Record Linkage (CHeReL) 2009).
The study period was defined as 1 January 2003 to 30
November 2011.
Selection of cohort

The cohort comprised women in the 45 and Up Study
with an incident dispensing of anastrozole, letrozole or
tamoxifen between July 2003 and December 2008 and a
diagnosis of invasive breast cancer listed on the Cancer
Registry. A six month washout period from January-June
2003 was used to remove the ‘prevalent pool’ of women
dispensed endocrine therapy. Women were excluded
from the analysis if they had either a distant tumour at
diagnosis, an initial dispensing date prior to diagnosis,
or a period >18 months between diagnosis and commencing endocrine therapy. The final study sample
comprised 1531 women.
Determining duration of endocrine therapy use

The supply period for all medicines was considered to
be pack size plus five days to allow for refill (i.e. 35 days)
with the exception of tamoxifen 20 mg which was 65 days.
Discontinuation was considered to have occurred if there
was no dispensing of any endocrine therapy (anastrozole, exemestane, letrozole or tamoxifen) for a period
of >180 days (Hershman et al. 2010; Nekhlyudov et al.
2011). Duration of endocrine therapy use was defined
in two ways: i) time to last recorded dispensing of the

Kemp et al. SpringerPlus 2014, 3:282
http://www.springerplus.com/content/3/1/282

participants’ initial endocrine therapy plus the supply
period and ii) time to last recorded dispensing of any
endocrine therapy plus the supply period.
Ascertaining comorbidities, recurrence and death

Comorbid anxiety, depression, hot flashes, musculoskeletal pain, osteoporosis and vaginal atrophy were ascertained by claims for ≥1 specified PBS items dispensed
during the study period (Table 1). PBS data do not capture information on indication, however, many items are
restricted to use for particular indications. For example,
PBS-supply of venlafaxine is restricted to use for major
depressive disorders (Australian Government Department
of Health 2013a). Comorbidities were considered to be
‘pre-existing’ if the relevant medication was dispensed
before the incident endocrine therapy and ‘newly-treated’
if dispensed for the first time after endocrine therapy
commenced. Breast cancer recurrence is not routinely collected in the Cancer Registry so was ascertained from: i)
specified surgeries, chemotherapy or radiotherapy occurring for the first time >18 months from the date of
diagnosis, or >12 months after previous claims for these
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events, or ii) first dispensing of a medicine indicated only
for advanced breast cancer (Table 1). Fact and date of
death were obtained from the death register for the years
2003–2010. Deaths occurring in 2011 were ascertained
from PBS data by having no dispensing for any medicines
for a period of >180 days. Deaths ascertained using this
algorithm were validated against the death register for the
period 2003–2010, with a resulting sensitivity and specificity of 98.2% and 90.2%, respectively. The algorithm
detected 98% of deaths to within 1 calendar month of the
date of death listed in the death register.
Other covariates

Tumour stage and size were obtained from the Cancer
Registry. Women undergoing mastectomy or chemotherapy prior to commencing endocrine therapy were
identified through specified hospital and MBS items
(Table 1). Specialty of the treating clinician was obtained
from participant’s MBS claims between diagnosis and
start of endocrine therapy (i.e. medical oncologist/other).
Residential location was assessed using the Accessibility/
Remoteness Index of Australia Plus (ARIA+) (Australian

Table 1 Medicine and service codes used to identify endocrine therapies, comorbidity and cancer recurrence, by data
source
Description

Name and item code

Pharmaceutical benefits scheme
Endocrine therapies subsidised for
early breast cancer

Anastrozole (8179L); exemestane (8506Q); letrozole (8245Y); tamoxifen (2109B, 2110C).

Anxiety treatments

Alprazolam (2130D, 2131E, 2132F, 8118G); diazepam (3161J, 3162K); oxazepam 3132W 3133X).

Depression treatments

Amitriptyline (2417F, 2418G, 2429W); citalopram (8220P, 8702B, 8703C); dothiepin (1357K, 1358L); doxepin
(1011F, 1012G, 1013H); escitalopram (8700X, 8701Y, 9433L, 9711D, 9727Y, 9728B); fluoxetine (1434L, 8270G);
fluvoxamine (8174F); imipramine (2421K); mianserin (1627P, 1628Q); moclobemide (1900B, 8003F);
mirtazapine (8513C, 8855C, 8856D, 8857E, 8883M); nortriptyline (2522R, 2323T); paroxetine (2242B);
reboxetine (8583R); sertraline (2236Q, 2237R, 8836C, 8837D); venlafaxinea (8068P, 8301X, 8302Y, 8868R).

Hot flash treatments

Clonidine (3141H, 3145M).

Musculoskeletal pain treatments

Celecoxib (8439E, 8440F), diclofenac (1299J, 1300K, 1332D), ibuprofen (3190X, 3192B, 3198H, 5121M,
5124Q), indomethacin (2454E, 2757D); ketoprofen (1588N, 1590Q); meloxicam (8561N, 8562P, 8887R, 8888T);
naproxen (1614Y, 1615B, 1659H, 1674D, 1795L); piroxicam (1895R, 1896T, 1897W, 1898X); rofecoxib
(8471W, 8472X); sulindac (2047R, 2048T); tiaprofenic acid (2103Q).

Osteoporosis treatments

Alendronate (8102K, 8511Y, 9012H, 9183H, 9351E); etidronate (8056B); risedronate (8481J, 8621R, 8899J,
9147K, 9391G); strontium (3036T); zoledronate (9288W).

Vaginal atrophy treatment

Oestriol (1771F, 1776L, 1781R).
b

Medicines for advanced breast cancer

Capecitabine (8362D, 8631C); lapatinib (9148L); medroxyprogesterone (2728N); megestrol (2734X),
toremifene (8216K); vinorelbine (8280T, 8281W, 9009E, 9010F).

Medicare benefits schedule
Chemotherapy

13915, 13918, 13921, 13924, 13927, 13930 13933, 13936.

Radiotherapy

15000-15012, 15100-15115, 15211-15217, 15219-15232, 15234-15247, 15249-15262, 15264-15272,
15303-15337, 15339-15357, 15339-15357.

Admitted patient data collection
Services for cancer recurrence

a

Chemotherapy (13915, 13918, 13921, 13924, 13927, 13930 13933, 13936); lumpectomy (31500, 31503,
31506, 31509, 31512); mastectomy (31518, 31524); oophorectomy (35638, 35673, 35712, 35716, 35717,
35753, 35754).

Venlafaxine subsidy is restricted to use for major depressive disorders but some off-label or dual use may occur for hot flashes.
These therapies are not subsidised for the treatment of early breast cancer.

b
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Population and Migration Research Centre 2013). Annual
household income, highest level of education, marital
status and country of birth were reported by participants
at recruitment to the 45 and Up Study. County of birth
was categorised as ‘Australia’, ‘New Zealand (NZ) or the
United Kingdom (UK)’, or ‘other countries’.
Statistical analysis

Kaplan-Meier curves were used to determine time from
first endocrine therapy dispensing until discontinuation
of initial therapy, and discontinuation of any therapy.
Follow-up was censored at five years after initial endocrine
dispensing, recurrence, death, or study end; whichever occurred first. Univariate and multivariate Cox-proportional
hazards models were used to determine the association
between a range of clinical and demographic characteristics with discontinuation of endocrine therapy before five
years (early discontinuation). All variables were included
in the multivariate (adjusted) models. Hazard ratios (HR)
and 95% confidence intervals (CI) were calculated for each
characteristic. All analyses were conducted using IBM
SPSS version 19.

Results
Time to discontinuation of endocrine therapy

The median time for participants to discontinue their
initial endocrine therapy was 2.2 years (range 0.8–4.9,
Figure 1). Use of initial therapy had ceased for 32% of
women at one year, increasing to 81% by five years. The
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median time for discontinuation of any endocrine therapy
was considerably longer at 4.8 years. Cumulative probability of discontinuing any endocrine therapy was 17% after
one year, 27% at two years, 31% at three years, and 58% by
five years.
Characteristics associated with discontinuation of initial
therapy

Time to discontinuation of initial therapy varied by therapy type in both the unadjusted and adjusted models
(Table 2). A history of anxiety, depression, hot flashes,
osteoporosis or vaginal atrophy before commencing
endocrine therapy did not impact on treatment duration.
However, women with pre-existing musculoskeletal pain
were significantly more likely to discontinue their initial
therapy compared with other women (adjusted HR = 1.3,
95% CI = 1.1–1.5). Women newly-treated for anxiety,
depression, flashes or vaginal atrophy after commencing
endocrine therapy discontinued therapy earlier than
women without these comorbidities but only newlytreated anxiety remained significant in the adjusted model
(HR = 1.5, 95% CI = 1.1–1.9). Age, year of diagnosis, stage
at diagnosis, no chemotherapy, no mastectomy and not
seeing a medical oncologist were not related to duration
of initial therapy in the adjusted model. Similarly, discontinuation of initial therapy was not associated with any
demographic factors in the adjusted model including
geographic remoteness, income, education, marital status
or birth country.

Figure 1 Kaplan-Meier graph showing time to discontinuation of initial endocrine therapy, and any endocrine therapy.
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Table 2 Results of unadjusted and adjusted Cox proportional hazards models for discontinuation of initial or any
endocrine therapy, by specified clinical and demographic characteristics
Clinical and demographic
characteristics

N (%)

Initial endocrine therapy

Any endocrine therapy

Unadjusted hazard ratio Adjusted hazard ratio Unadjusted hazard ratio Adjusted hazard ratio
(95% CI)
(95% CI)
(95% CI)
(95% CI)

Initial therapy:
Tamoxifen

917 (59.9%)

1.00

1.00

1.00

1.00

Anastrozole

518 (33.8%)

0.53 (0.46–0.61)

0.57 (0.48–0.67)

0.64 (0.54–0.76)

0.90 (0.74–1.09)

96 (6.3%)

0.60 (0.45–0.80)

0.65 (0.49–0.87)

0.75 (0.53–1.07)

1.04 (0.72–1.50)

Letrozole
Year of diagnosis:
≥2004

1297 (84.7%)

1.00

1.00

1.00

1.00

<2004

234 (15.3%)

1.77 (1.52–2.06)

0.89 (0.63–1.25)

2.26 (2.16–3.04)

1.56 (1.01–2.40)

<55 years

454 (29.7%)

1.00

1.00

1.00

1.00

55–74 years

878 (57.3%)

0.93 (0.82–1.07)

1.03 (0.88–1.20)

1.08 (0.91–1.28)

1.07 (0.88–1.29)

≥75 years

199 (13.0%)

0.76 (0.62–0.94)

0.79 (0.62–1.01)

1.22 (0.96–1.55)

1.31 (0.98–1.75)

>2 cm

533 (34.8%)

1.00

1.00

1.00

1.00

<1–2 cm

528 (34.5%)

1.02 (0.88–1.19)

0.94 (0.80–1.11)

1.09 (0.90–1.32)

0.90 (0.73–1.11)

≤1 cm

176 (11.5%)

1.01 (0.82–1.25)

0.84 (0.67–1.06)

1.47 (1.15–1.90)

1.13 (0.86–1.48)

Missing

294 (19.2%)

1.75 (1.49–2.06)

1.43 (1.03–2.00)

2.52 (2.07–3.07)

1.25 (0.82–1.91)

Age:

Tumour size:

Stage:
Node-positive

608 (39.7%)

1.00

1.00

1.00

1.00

Node-negative

865 (56.5%)

1.07 (0.94–1.21)

0.96 (0.84–1.10)

1.37 (1.16–1.60)

1.15 (0.97–1.36)

Missing

58 (3.8%)

1.16 (0.85–1.60)

0.89 (0.63–1.26)

1.28 (0.85–1.94)

0.73 (0.47–1.14)

No chemotherapy

1145 (74.7%)

1.26 (1.09–1.46)

1.05 (0.87–1.26)

2.12 (1.72–2.62)

1.42 (1.11–1.83)

No mastectomy

1103 (72.0%)

1.21 (1.06–1.39)

1.06 (0.91–1.23)

1.77 (1.47–2.13)

1.45 (1.18–1.77)

No medical oncologista

922 (60.2%)

1.16 (1.02–1.32)

1.05 (0.90–1.23)

1.84 (1.55–2.17)

1.20 (0.98–1.48)

Anxiety

111 (7.3%)

1.00 (0.78–1.27)

1.00 (0.78–1.30)

0.99 (0.74–1.33)

1.09 (0.79–1.50)

Depression

271 (17.7%)

1.00 (0.85–1.18)

0.97 (0.81–1.16)

1.11 (0.91–1.35)

1.11 (0.91–1.36)

Hot flashes

14 (0.9%)

0.80 (0.40–1.60)

0.93 (0.46–1.90)

0.88 (0.39–1.96)

0.86 (0.38–1.95)

Pre-existing comorbidities:

Musculoskeletal pain

368 (24.0%)

1.10 (0.96–1.27)

1.25 (1.06–1.48)

1.06 (0.89–1.27)

0.95 (0.77–1.17)

Osteoporosis

86 (5.6%)

0.81 (0.61–1.07)

0.77 (0.57–1.04)

0.91 (0.65–1.28)

0.84 (0.59–1.21)

Vaginal atrophy

43 (2.8%)

1.08 (0.74–1.57)

1.27 (0.87–1.87)

1.05 (0.65–1.67)

1.06 (0.66–1.72)

Newly-treated comorbidities:
Anxiety
Depression
Hot flashes

78 (5.1%)

1.55 (1.20–1.99)

1.45 (1.11–1.90)

1.46 (1.08–1.97)

1.09 (0.79–1.50)

271 (17.7%)

1.19 (1.02–1.38)

1.10 (0.93–1.30)

1.09 (0.90–1.31)

1.11 (0.91–1.37)

28 (1.8%)

1.56 (1.03–2.36)

1.16 (0.76–1.79)

2.33 (1.51–3.60)

2.07 (1.32–3.27)

Musculoskeletal pain

328 (21.4%)

1.14 (0.99–1.32)

1.15 (0.98–1.35)

1.03 (0.86–1.23)

0.90 (0.73–1.09)

Osteoporosis

175 (11.4%)

0.89 (0.74–1.08)

0.93 (0.76–1.14)

0.94 (0.74–1.18)

0.88 (0.69–1.12)

60 (3.9%)

1.56 (1.18–2.06)

1.31 (0.98–1.75)

1.56 (1.13–2.16)

1.33 (0.95–1.88)

Major city

690 (45.1%)

1.00

1.00

1.00

1.00

Regional

544 (35.5%)

1.05 (0.92–1.21)

1.08 (0.94–1.24)

1.12 (0.95–1.32)

1.10 (0.93–1.31)

Remote

297 (19.4%)

0.96 (0.81–1.13)

0.94 (0.79–1.12)

0.97 (0.79–1.19)

0.93 (0.75–1.15)

Vaginal atrophy
Location:
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Table 2 Results of unadjusted and adjusted Cox proportional hazards models for discontinuation of initial or any
endocrine therapy, by specified clinical and demographic characteristics (Continued)
Household income:
≥$70,000

272 (17.8%)

1.00

1.00

1.00

1.00

$30,000-$69,999

369 (24.1%)

0.95 (0.79–1.14)

0.94 (0.77–1.14)

1.04 (0.82–1.31)

1.02 (0.79–1.30)

<$30,000

477 (31.2%)

0.93 (0.78–1.11)

0.95 (0.76–1.17)

1.13 (0.91–1.41)

1.09 (0.83–1.42)

Refused

413 (27.0%)

0.80 (0.67–0.96)

0.82 (0.67–1.01)

0.96 (0.77–1.21)

0.90 (0.69–1.17)

Undergraduate degree

330 (21.5%)

1.00

1.00

1.00

1.00

Certificate or diploma

395 (25.8%)

0.92 (0.77–1.09)

0.86 (0.72–1.03)

1.01 (0.82–1.25)

0.94 (0.75–1.17)

High school or less

777 (50.7%)

0.87 (0.75–1.02)

0.88 (0.74–1.04)

0.95 (0.79–1.15)

0.89 (0.72–1.10)

30 (2.0%)

0.84 (0.53–1.34)

0.85 (0.52–1.38)

1.03 (0.59–1.82)

0.90 (0.50–1.63)

Education:

Missing
Marital status:
Partner or spouse
Single
Separated or widowed

1084 (70.8%)

1.00

1.00

1.00

1.00

79 (5.2%)

1.08 (0.83–1.41)

1.06 (0.80–1.40)

1.12 (0.81–1.55)

1.04 (0.74–1.46)

369 (24.1%)

0.93 (0.80–1.07)

0.95 (0.81–1.11)

1.00 (0.84–1.19)

0.87 (0.72–1.06)

Birth country:
Australia

1143 (74.7%)

1.00

1.00

1.00

1.00

NZ, UKb

188 (12.3%)

1.14 (0.95–1.36)

1.19 (0.99–1.43)

1.42 (1.14–1.76)

1.56 (1.16–2.10)

Other

200 (13.1%)

0.94 (0.78–1.13)

0.90 (0.75–1.09)

0.93 (0.74–1.17)

1.04 (0.83–1.32)

(Bolded figures indicate P < 0.05).
a
Prior to commencing endocrine therapy.
b
New Zealand, United Kingdom.

Characteristics associated with discontinuation of any
endocrine therapy

Women commencing therapy with anastrozole were
less likely to discontinue any endocrine therapy than
those initiated on tamoxifen (unadjusted HR = 0.6, 95%
CI = 0.5–0.8); however this relationship was not significant
in the adjusted model (Table 2). None of the pre-existing
comorbidities examined predicted duration of endocrine
therapy in the unadjusted or adjusted models. Newlytreated anxiety, hot flashes and vaginal atrophy were
associated with discontinuation of any therapy in the
unadjusted models but only hot flashes remained significant after adjusting for other variables (HR = 2.1,
95% CI = 1.3–3.3).
Clinical characteristics including age, tumour size and
stage were not associated with discontinuation of therapy
in the adjusted models. However, women not undergoing
chemotherapy or mastectomy prior to endocrine therapy
were significantly more likely to discontinue therapy by
five years compared with women who did receive these
treatments (adjusted model, chemotherapy HR = 1.4, 95%
CI = 1.1–1.8; mastectomy HR = 1.5, 95% CI = 1.2–1.8).
Women born in the UK or NZ were significantly more
likely to discontinue endocrine therapy than Australianborn women (HR = 1.6, 95% CI = 1.2–2.1). No other demographic characteristics were related to duration of
therapy in the unadjusted or adjusted models.

Discussion
Only 19% of women receiving endocrine therapy for
early breast cancer in clinical practice continued to use
their initial therapy for five years. When allowing for
switching between therapies, the proportion of women
using any endocrine therapy for five years, as consistently recommended by clinical trial evidence (ATAC
Trialists’ Group 2005; Bliss et al. 2012; Coates et al.
2007; Davies and (ATLAS) (2013); Forbes et al. 2008;
Gray and aTTom Collaborative Group 2013), was 42%.
These suboptimal persistence rates are similar to discontinuation rates of 31–73% by five years reported elsewhere (Murphy et al. 2012). The extent of early
discontinuation of all endocrine therapy observed here
suggests that more than half of treated women do not
obtain the benefits of endocrine therapy demonstrated
in clinical trials (Hsieh et al. 2014; McCowan et al. 2008;
Swedish Breast Cancer Cooperative Group 1996; Yood
et al. 2008). Given that tamoxifen duration is now recommended to be 10 years based on ATLAS and aTTom
data, this suboptimal efficacy is likely to be magnified in
the future (Davies and (ATLAS) (2013); Gray and
aTTom Collaborative Group 2013).
We observed different predictors for discontinuation
of initial therapy compared with any endocrine therapy.
Women were more likely to discontinue their initial
therapy if they commenced with tamoxifen, had pre-
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existing arthritis, or were newly-treated for anxiety. The
finding that women discontinued initial therapy with
tamoxifen earlier than women initiated on anastrozole
or letrozole is unsurprising given that trial evidence and
clinical guidelines support a switch from tamoxifen to an
aromatase inhibitor after 2–3 years for post-menopausal
women (Baum et al. 2003; National Breast Cancer Centre
(NBCC) and National Health and Medical Research
Council (NHMRC) 2001; Winer et al. 2005). Given that
tamoxifen is the only endocrine therapy recommended for
pre- or peri-menopausal, it is more likely that women
would switch from tamoxifen to AIs as therapy progresses
than the converse (Cheung 2007; NBCC and NHMRC
2001). Switching from tamoxifen to an AI, rather than the
converse, is also more likely because our study covers the
period before release of the BIG 1–98 results, which supports use of AIs before a switch to tamoxifen in low and
intermediate risk women (Viale et al. 2011). It is encouraging to note that initial therapy type did not influence
the total duration of endocrine therapy for women in this
study, nor did the other predictors of initial therapy
discontinuation: pre-existing musculoskeletal pain and
newly-treated anxiety.
Our results showed that the women most likely to
discontinue any endocrine therapy before five years were
those who did not undergo chemotherapy or mastectomy.
This finding remained after adjusting for treatment by a
medical oncologist. Previous studies have reported that
women not undergoing chemotherapy or mastectomy are
more likely to discontinue therapy early. A large observational study of 8769 women followed for 4.5 years found
that women undergoing chemotherapy before commencing endocrine therapy were significantly less likely to
discontinue than other women, and those who had undergone mastectomy were less likely to discontinue than
those who had a lumpectomy (Hershman et al. 2010). A
shorter-term study (1 year follow-up) of >13,000 women
also reported that women with pre-endocrine therapy
mastectomy had nearly half the probability of nonadherence compared with women without mastectomy
(Sedjo and Devine 2011). It may be that women who
undergo more ‘aggressive’ treatments perceive their condition as more serious and their need for endocrine therapy
greater, than other women.
Women in this study first treated for hot flashes after
commencing endocrine therapy were at higher risk of
early discontinuation than other women. Hot flashes
were the side-effect women most commonly cited for
discontinuing tamoxifen in Swiss (N = 400) and UK studies
(N = 110) (Charlson et al. 1987; Neugut et al. 2011). Anecdotally, women describe hot flashes as causing sleep disturbance, difficulty concentrating and decreased quality of
life. It is interesting to note that only newly-treated, and
not pre-existing, hot flashes were associated with early
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discontinuation. None of the other pre-existing or newlytreated comorbidites we examined were associated with
early discontinuation of any endocrine therapy. We may
have underestimated treatment for hot flashes in this
group because our data did not include non-PBS supply of
medicines which might be used for flushing (such as
gabapentin and venlafaxine, which are restricted to use for
epilepsy and major depression, respectively) (Australian
Government Department of Health 2013a).
It is not clear why women born in NZ or the UK would
discontinue endocrine therapy earlier than Australianborn women. All of the women in the study were residents of NSW at recruitment to the 45 and Up Study
(2006–2009) and reported a median duration of residence
in Australia of 37 years (range 26–47). NZ and the UK are
culturally similar to Australia, have comparable public
pharmaceutical insurance (Kemp et al. 2010), and NZ and
UK immigrants to Australia are the most frequent of any
countries (Australian Bureau of Statistics 2013). Therefore
we consider it unlikely that social marginalisation or
unfamiliarity with the health system underpins this higher
discontinuation. Further research with this group of women
is needed to understand the increased risk of early discontinuation observed here or indeed see if this represents
just a spurious finding.
Strengths and weaknesses

To our knowledge, this is the first observational study
with follow-up >2 years to examine the impact of initial
therapy and specific comorbidities on discontinuation of
initial endocrine therapy and any endocrine therapy.
Many studies with long follow-up have only examined
tamoxifen discontinuation (Barron et al. 2007; Huiart
et al. 2011; McCowan et al. 2008; Partridge et al. 2003),
and have examined number of comorbidities rather than
specific conditions (Kimmick et al. 2009; McCowan
et al. 2008; Nekhlyudov et al. 2011; Neugut et al. 2011;
van Herk-Sukel et al. 2010; Weaver et al. 2013). Our
study is also the first observational study investigating
duration of endocrine therapy in Australian clinical
practice. Australia’s PBS provides subsidised prescription
medicines for all Australian residents at relatively low
cost (up to AUSa $5.60 and $34.20 per item for social
security recipients and other beneficiaries, respectively,
as of study end in 2011 (Australian Government Department of Health 2013b; Organisation for Economic
Co-operation and Development 2014); therefore cost
may be less of a barrier to use in Australia than in some
other countries (Kemp et al. 2011).
We used health records for a heterogeneous community sample for whom all publically-subsidised endocrine
therapies have been captured. We were able to follow
women for up to five years after commencing their initial therapy, with a minimum follow-up time of 2.9 years.
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The findings reported here are comparable to those
in previous observational studies of discontinuation as
the same definition of discontinuation has been used
(180 days), and follow-up was similarly censored for
recurrence and death (Barron et al. 2007; Hershman et al.
2010; Nekhlyudov et al. 2011; van Herk-Sukel et al. 2010).
Women experiencing troubling side-effects may take a
‘drug holiday’ from endocrine therapy for up to 3 months
(Jordan et al. 2011; Sehdev et al. 2009), and so our use of
180 days to define discontinuation would avoid misclassification of these women.
There are limitations to this study. Our sample was
drawn from the 45 and Up Study, limiting the sample to
individual’s ≥45 years and consenting to linkage of their
health records. The health service history of such individuals may differ from younger people, or those who do
not agree to participate in cohort studies. Although
we could not directly ascertain whether participants
had hormone-dependent tumours, endocrine therapies
in Australia are only publically-subsidised for hormonedependent tumours (Australian Government Department
of Health 2013a). We could not directly assess cancer
recurrence and had to ‘triangulate’ using medicines and
services used to treat recurrence. This method of ascertaining breast cancer recurrence has been successfully
demonstrated using administrative health service data in
previous studies (Earle et al. 2002; Lamont et al. 2006;
Stokes et al. 2008). The validity of recurrence using this
method has also been compared with chart review with
a reported sensitivity and specificity of 92% and 94%
respectively (Earle et al. 2002).
We were limited to analysing dispensing of endocrine
therapy rather than actual consumption. It is not possible
to determine whether prescriptions were filled but not
taken by women in this study, and similarly women who
were prescribed but never dispensed their initial endocrine therapy were not captured. Despite this limitation,
prescription refills are used as a measure of adherence and
persistence in many endocrine therapy duration studies
(Hershman et al. 2010; Huiart et al. 2011; Murphy et al.
2012; van Herk-Sukel et al. 2010) and are consisted an
objective and accurate proxy for actual intake (NBCC and
NHMRC 2001).

Conclusion
Less than half of women in this study (42%) completed
five years of endocrine therapy for breast cancer. This
suboptimal use means that the full benefit of endocrine
therapies in reducing recurrence and cancer-related
mortality consistently demonstrated in clinical trials may
not be realised in practice. Choice of initial endocrine
therapy, pre-existing musculoskeletal pain and newlytreated anxiety were related to shorter duration of initial
therapy but not early discontinuation of any therapy.
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Women at greatest risk of stopping any endocrine therapy
before the recommended five years were those receiving
less aggressive initial treatment (i.e. no chemotherapy or
mastectomy), those with newly-treated flashes, and those
born in UK or NZ. Strategies are needed to support medicine use and improve outcomes for these women.
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